TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Gao, Xin ^a   Zhu, Yibei ^a,b   Li, Gang ^a   Huang, Haitao ^d   Zhang, Guangbo ^d   Wang, Fengming ^a   Sun, Jing ^a   Yang, Qianting ^e   Zhang, Xueguang ^a   Lu, Binfeng ^b,c  

^a SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^e SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; T CELL IMMUNOGLOBULIN 3; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; HAVCR2 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CANCER TRANSPLANTATION; DISEASE COURSE; DISEASE MODEL; IMMUNOLOGY; LUNG TUMOR; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; UPREGULATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-GAMMA; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 84857159981     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030676     Document Type: Article

References (21)

1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
2. Zou W, (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274.
3. Zou W, (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307.
4. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, et al. (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207: 2175-2186.
5. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, et al. (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207: 2187-2194.
6. Li MO, Flavell RA, (2008) Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity 28: 468-476.
7. Zou W, Chen L, (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8: 467-477.
8. Lu B, Chen L, Liu L, Zhu Y, Wu C, et al. (2011) T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol Res 50: 269-275.
9. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, et al. (2007) Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 318: 1141-1143.
10. Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, et al. (2009) TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 39: 2492-2501.
11. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, et al. (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415: 536-541.
12. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, et al. (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6: 1245-1252.
13. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, et al. (2003) Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 4: 1102-1110.
14. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, et al. (2003) Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 4: 1093-1101.
15. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, et al. (2008) Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205: 2763-2779.
16. Zhu Y, Ju S, Chen E, Dai S, Li C, et al. (2010) T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J Immunol 185: 3174-3183.
17. Williams LM, Rudensky AY, (2007) Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 8: 277-284.
18. Boenisch O, D'Addio F, Watanabe T, Elyaman W, Magee CN, et al. (2010) TIM-3: a novel regulatory molecule of alloimmune activation. J Immunol 185: 5806-5819.
19. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, et al. (2008) Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A 105: 9331-9336.
20. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, et al. (2008) Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 127: 78-88.
21. Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK, (2011) Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol 21: 21.